GlassScriptPhysician profile
Veronica N Shaw
NPI 1346660701
$4,942.18
in general payments reported to CMS, 2019-2025
21 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $805 · 2022: $504 · 2023: $475 · 2024: $2,062 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,952 · Travel and Lodging: $645 · Education: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,951.59 |
| Travel and Lodging | $644.81 |
| Education | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,500.66 | 2021-2025 | Synchromedii, Intellis Adaptivestim |
| Abbvie INC. | $942.19 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $433.30 | 2021-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $307.26 | 2021-2025 | Xtampza |
| Scilex Pharmaceuticals INC. | $264.80 | 2021-2025 | Ztlido |
| Pfizer INC. | $256.56 | 2023-2025 | |
| Saluda Medical Americas, INC. | $223.93 | 2025 | Evoke |
| Biohaven Pharmaceuticals, INC. | $213.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $188.19 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $142.52 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $69.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $68.19 | 2021 | |
| Azurity Pharmaceuticals, INC. | $66.72 | 2024-2025 | Horizant |
| Biotronik Nro, INC. | $50.83 | 2024 | Prospera |
| Tonix Medicines, INC. | $45.17 | 2025 | Tonmya |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mml US, INC. | $39.52 | 2025 | Reactiv8 |
| Bioventus LLC | $38.64 | 2022-2023 | Durolane |
| Abbott Laboratories | $33.74 | 2024 | Proclaim, Eterna |
| Curonix LLC | $31.76 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Kowa Pharmaceuticals America, INC. | $12.64 | 2022 | |
| Spr Therapeutics, INC | $12.27 | 2024 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.